Modulation of farnesoid X receptor results in post-translational modification of poly (ADP-ribose) polymerase 1 in the liver

Yan Zhu, Guodong Li, Yafeng Dong, Helen H. Zhou, Bo Kong, Lauren Aleksunes, Jason R. Richardson, Fei Li, Grace Guo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The farnesoid X receptor (FXR) is a bile acid-activated transcription factor belonging to the nuclear receptor superfamily. FXR deficiency in mice results in cholestasis, metabolic disorders, and tumorigenesis in liver and intestine. FXR is known to contribute to pathogenesis by regulating gene transcription; however, changes in the post-transcriptional modification of proteins associated with FXR modulation have not been determined. In the current study, proteomic analysis of the livers of wild-type (WT) and FXR knockout (FXR-KO) mice treated with a FXR synthetic ligand or vehicle was performed. The results identified five proteins as novel FXR targets. Since FXR deficiency in mice leads to liver tumorigenesis, poly (ADP-ribose) polymerase family, member 1 (Parp1) that is important for DNA repair, was validated in the current study by quantitative real-time PCR, and 1- and 2-dimensional gel electrophoresis/western blot. The results showed that Parp1 mRNA levels were not altered by FXR genetic status or by agonist treatment. However, total Parp1 protein levels were increased in FXR-KO mice as early as 3. month old. Interestingly, total Parp1 protein levels were increased in WT mice in an age-dependent manner (from 3 to 18. months), but not in FXR-KO mice. Finally, activation of FXR in WT mice resulted in reduction of phosporylated Parp1 protein in the liver without affecting total Parp1 protein levels. In conclusion, this study reveals that FXR genetic status and agonist treatment affects basal levels and phosphorylation state of Parp1, respectively. These alterations, in turn, may be associated with the hepatobiliary alterations observed in FXR-KO mice and participate in FXR agonist-induced protection in the liver.

Original languageEnglish (US)
Pages (from-to)260-266
Number of pages7
JournalToxicology and Applied Pharmacology
Volume266
Issue number2
DOIs
StatePublished - Jan 5 2013

Fingerprint

Poly(ADP-ribose) Polymerases
Post Translational Protein Processing
Liver
Modulation
Proteins
Artificial Receptors
Carcinogenesis
Phosphorylation
Transcription
Cytoplasmic and Nuclear Receptors
Electrophoresis
Bile Acids and Salts
Cholestasis
Poly (ADP-Ribose) Polymerase-1
Knockout Mice
DNA Repair
Proteomics
Repair
Transcription Factors
Intestines

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology

Keywords

  • Farnesoid X receptor
  • Mice
  • Nuclear receptor
  • Parp1
  • Post-translational modification
  • Proteomics

Cite this

Zhu, Yan ; Li, Guodong ; Dong, Yafeng ; Zhou, Helen H. ; Kong, Bo ; Aleksunes, Lauren ; Richardson, Jason R. ; Li, Fei ; Guo, Grace. / Modulation of farnesoid X receptor results in post-translational modification of poly (ADP-ribose) polymerase 1 in the liver. In: Toxicology and Applied Pharmacology. 2013 ; Vol. 266, No. 2. pp. 260-266.
@article{063a714e99bc40428a3a26e4c471c590,
title = "Modulation of farnesoid X receptor results in post-translational modification of poly (ADP-ribose) polymerase 1 in the liver",
abstract = "The farnesoid X receptor (FXR) is a bile acid-activated transcription factor belonging to the nuclear receptor superfamily. FXR deficiency in mice results in cholestasis, metabolic disorders, and tumorigenesis in liver and intestine. FXR is known to contribute to pathogenesis by regulating gene transcription; however, changes in the post-transcriptional modification of proteins associated with FXR modulation have not been determined. In the current study, proteomic analysis of the livers of wild-type (WT) and FXR knockout (FXR-KO) mice treated with a FXR synthetic ligand or vehicle was performed. The results identified five proteins as novel FXR targets. Since FXR deficiency in mice leads to liver tumorigenesis, poly (ADP-ribose) polymerase family, member 1 (Parp1) that is important for DNA repair, was validated in the current study by quantitative real-time PCR, and 1- and 2-dimensional gel electrophoresis/western blot. The results showed that Parp1 mRNA levels were not altered by FXR genetic status or by agonist treatment. However, total Parp1 protein levels were increased in FXR-KO mice as early as 3. month old. Interestingly, total Parp1 protein levels were increased in WT mice in an age-dependent manner (from 3 to 18. months), but not in FXR-KO mice. Finally, activation of FXR in WT mice resulted in reduction of phosporylated Parp1 protein in the liver without affecting total Parp1 protein levels. In conclusion, this study reveals that FXR genetic status and agonist treatment affects basal levels and phosphorylation state of Parp1, respectively. These alterations, in turn, may be associated with the hepatobiliary alterations observed in FXR-KO mice and participate in FXR agonist-induced protection in the liver.",
keywords = "Farnesoid X receptor, Mice, Nuclear receptor, Parp1, Post-translational modification, Proteomics",
author = "Yan Zhu and Guodong Li and Yafeng Dong and Zhou, {Helen H.} and Bo Kong and Lauren Aleksunes and Richardson, {Jason R.} and Fei Li and Grace Guo",
year = "2013",
month = "1",
day = "5",
doi = "10.1016/j.taap.2012.11.012",
language = "English (US)",
volume = "266",
pages = "260--266",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "2",

}

Modulation of farnesoid X receptor results in post-translational modification of poly (ADP-ribose) polymerase 1 in the liver. / Zhu, Yan; Li, Guodong; Dong, Yafeng; Zhou, Helen H.; Kong, Bo; Aleksunes, Lauren; Richardson, Jason R.; Li, Fei; Guo, Grace.

In: Toxicology and Applied Pharmacology, Vol. 266, No. 2, 05.01.2013, p. 260-266.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Modulation of farnesoid X receptor results in post-translational modification of poly (ADP-ribose) polymerase 1 in the liver

AU - Zhu, Yan

AU - Li, Guodong

AU - Dong, Yafeng

AU - Zhou, Helen H.

AU - Kong, Bo

AU - Aleksunes, Lauren

AU - Richardson, Jason R.

AU - Li, Fei

AU - Guo, Grace

PY - 2013/1/5

Y1 - 2013/1/5

N2 - The farnesoid X receptor (FXR) is a bile acid-activated transcription factor belonging to the nuclear receptor superfamily. FXR deficiency in mice results in cholestasis, metabolic disorders, and tumorigenesis in liver and intestine. FXR is known to contribute to pathogenesis by regulating gene transcription; however, changes in the post-transcriptional modification of proteins associated with FXR modulation have not been determined. In the current study, proteomic analysis of the livers of wild-type (WT) and FXR knockout (FXR-KO) mice treated with a FXR synthetic ligand or vehicle was performed. The results identified five proteins as novel FXR targets. Since FXR deficiency in mice leads to liver tumorigenesis, poly (ADP-ribose) polymerase family, member 1 (Parp1) that is important for DNA repair, was validated in the current study by quantitative real-time PCR, and 1- and 2-dimensional gel electrophoresis/western blot. The results showed that Parp1 mRNA levels were not altered by FXR genetic status or by agonist treatment. However, total Parp1 protein levels were increased in FXR-KO mice as early as 3. month old. Interestingly, total Parp1 protein levels were increased in WT mice in an age-dependent manner (from 3 to 18. months), but not in FXR-KO mice. Finally, activation of FXR in WT mice resulted in reduction of phosporylated Parp1 protein in the liver without affecting total Parp1 protein levels. In conclusion, this study reveals that FXR genetic status and agonist treatment affects basal levels and phosphorylation state of Parp1, respectively. These alterations, in turn, may be associated with the hepatobiliary alterations observed in FXR-KO mice and participate in FXR agonist-induced protection in the liver.

AB - The farnesoid X receptor (FXR) is a bile acid-activated transcription factor belonging to the nuclear receptor superfamily. FXR deficiency in mice results in cholestasis, metabolic disorders, and tumorigenesis in liver and intestine. FXR is known to contribute to pathogenesis by regulating gene transcription; however, changes in the post-transcriptional modification of proteins associated with FXR modulation have not been determined. In the current study, proteomic analysis of the livers of wild-type (WT) and FXR knockout (FXR-KO) mice treated with a FXR synthetic ligand or vehicle was performed. The results identified five proteins as novel FXR targets. Since FXR deficiency in mice leads to liver tumorigenesis, poly (ADP-ribose) polymerase family, member 1 (Parp1) that is important for DNA repair, was validated in the current study by quantitative real-time PCR, and 1- and 2-dimensional gel electrophoresis/western blot. The results showed that Parp1 mRNA levels were not altered by FXR genetic status or by agonist treatment. However, total Parp1 protein levels were increased in FXR-KO mice as early as 3. month old. Interestingly, total Parp1 protein levels were increased in WT mice in an age-dependent manner (from 3 to 18. months), but not in FXR-KO mice. Finally, activation of FXR in WT mice resulted in reduction of phosporylated Parp1 protein in the liver without affecting total Parp1 protein levels. In conclusion, this study reveals that FXR genetic status and agonist treatment affects basal levels and phosphorylation state of Parp1, respectively. These alterations, in turn, may be associated with the hepatobiliary alterations observed in FXR-KO mice and participate in FXR agonist-induced protection in the liver.

KW - Farnesoid X receptor

KW - Mice

KW - Nuclear receptor

KW - Parp1

KW - Post-translational modification

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=84871830086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871830086&partnerID=8YFLogxK

U2 - 10.1016/j.taap.2012.11.012

DO - 10.1016/j.taap.2012.11.012

M3 - Article

C2 - 23178280

AN - SCOPUS:84871830086

VL - 266

SP - 260

EP - 266

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 2

ER -